247 related articles for article (PubMed ID: 27811123)
1. Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up
Taghipour M; Marcus C; Sheikhbahaei S; Mena E; Prasad S; Jha AK; Solnes L; Subramaniam RM
J Nucl Med; 2017 May; 58(5):737-743. PubMed ID: 27811123
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management.
Marcus C; Paidpally V; Antoniou A; Zaheer A; Wahl RL; Subramaniam RM
J Nucl Med; 2015 Feb; 56(2):204-8. PubMed ID: 25613535
[TBL] [Abstract][Full Text] [Related]
4. The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin's lymphoma.
Taghipour M; Marcus C; Jones S; Sarangi R; Trahan TJ; Subramaniam RM
Nucl Med Commun; 2016 Jul; 37(7):699-704. PubMed ID: 26990623
[TBL] [Abstract][Full Text] [Related]
5. ¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
Marcus C; Marashdeh W; Ahn SJ; Taghipour M; Subramaniam RM
J Nucl Med; 2015 Jul; 56(7):989-94. PubMed ID: 25952738
[TBL] [Abstract][Full Text] [Related]
6. Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.
Taghipour M; Sheikhbahaei S; Trahan TJ; Subramaniam RM
Nucl Med Commun; 2016 Jun; 37(6):602-8. PubMed ID: 27110955
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
8. The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer.
Sheikhbahaei S; Mena E; Yanamadala A; Reddy S; Solnes LB; Wachsmann J; Subramaniam RM
AJR Am J Roentgenol; 2017 Feb; 208(2):420-433. PubMed ID: 27726427
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
10. Performance of whole-body
Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z
Eur Arch Otorhinolaryngol; 2019 Mar; 276(3):847-855. PubMed ID: 30604061
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Brain Metastases on Follow-up
Nia ES; Garland LL; Eshghi N; Nia BB; Avery RJ; Kuo PH
J Nucl Med Technol; 2017 Sep; 45(3):193-197. PubMed ID: 28705927
[TBL] [Abstract][Full Text] [Related]
12. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
14. Primary Tumor ¹⁸F-FDG Avidity Affects the Performance of ¹⁸F-FDG PET/CT for Detecting Gastric Cancer Recurrence.
Kim SJ; Cho YS; Moon SH; Bae JM; Kim S; Choe YS; Kim BT; Lee KH
J Nucl Med; 2016 Apr; 57(4):544-50. PubMed ID: 26678615
[TBL] [Abstract][Full Text] [Related]
15. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1081-8. PubMed ID: 18180917
[TBL] [Abstract][Full Text] [Related]
16. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors.
Scanga DR; Martin WH; Delbeke D
Clin Nucl Med; 2004 Feb; 29(2):86-90. PubMed ID: 14734903
[TBL] [Abstract][Full Text] [Related]
17. Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma: Value to Clinical Assessment and Patient Management.
Taghipour M; Marcus C; Nunna P; Subramaniam RM
Clin Nucl Med; 2016 Feb; 41(2):e93-7. PubMed ID: 26545018
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
20. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
